These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8549381)

  • 41. Current status of antibiotic treatment for Mycoplasma pneumoniae infections.
    McCracken GH
    Pediatr Infect Dis; 1986; 5(1):167-71. PubMed ID: 3080736
    [No Abstract]   [Full Text] [Related]  

  • 42. Constrictive pericarditis secondary to infection with Mycoplasma pneumoniae.
    Hawkins S; Rausch CM; McCanta AC
    Curr Opin Pediatr; 2011 Feb; 23(1):126-9. PubMed ID: 21107263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Synthesis and antibacterial activities of 1-amino-6-fluoro-1,4-dihydro-4-oxo-7-(substituted) piperazinyl-3-quinolinecarboxylic acids and their derivatives].
    Xin T; Ding J; Zhang XP
    Yao Xue Xue Bao; 1993; 28(11):865-9. PubMed ID: 8010004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008-2015.
    Tanaka T; Oishi T; Miyata I; Wakabayashi S; Kono M; Ono S; Kato A; Fukuda Y; Saito A; Kondo E; Teranishi H; Tanaka Y; Wakabayashi T; Akaike H; Ogita S; Ohno N; Nakano T; Terada K; Ouchi K
    Emerg Infect Dis; 2017 Oct; 23(10):1703-1706. PubMed ID: 28930026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Dalhoff A
    Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301
    [No Abstract]   [Full Text] [Related]  

  • 46. Management of macrolide-resistant Mycoplasma pneumoniae infection.
    Saegeman V; Proesmans M; Dumke R
    Pediatr Infect Dis J; 2012 Nov; 31(11):1210-1. PubMed ID: 22668803
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
    Molinari G; Schito GC
    Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
    Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
    Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 50. Resistance of Mycoplasma pneumoniae to erythromycin: a clinical case with severe pulmonary, cerebral and systemic complications.
    Clara F; Von Busch C; Goeddertz P; Novotna I
    J Chemother; 1989 Jul; 1(4 Suppl):411-3. PubMed ID: 16312462
    [No Abstract]   [Full Text] [Related]  

  • 51. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 52. Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():226-7. PubMed ID: 8549311
    [No Abstract]   [Full Text] [Related]  

  • 53. [Analysis on antibacterial activity of common antibiotics to Mycoplasma pneumoniae].
    Xin DL; Chen XG; Han X
    Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):305-6. PubMed ID: 19555573
    [No Abstract]   [Full Text] [Related]  

  • 54. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC; Foleno BD; Fu KP
    Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New generations of quinolones: with particular attention to levofloxacin.
    Ambrose PG; Owens RC; Quintiliani R; Nightingale CH
    Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076
    [No Abstract]   [Full Text] [Related]  

  • 56. [Efficacy of lomefloxacin in treatment of nonspecific inflammatory diseases and in prophylaxis of postoperative complications in urology].
    Derevianko II; Khodyreva LA; Avdoshin VL; Andriukhin MI; Gabliia MIu
    Antibiot Khimioter; 1998; 43(10):36-41. PubMed ID: 9825109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative in vitro activity of BAY Y 3118 against selected species.
    Verbist L; Verhaegen J
    Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.
    Tagliabue C; Techasaensiri C; Torres JP; Katz K; Meek C; Kannan TR; Coalson JJ; Esposito S; Principi N; Leff R; Baseman JB; Hardy RD
    J Antimicrob Chemother; 2011 Oct; 66(10):2323-9. PubMed ID: 21791441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
    Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5317-8. PubMed ID: 19738013
    [No Abstract]   [Full Text] [Related]  

  • 60. Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
    Sakurai N; Sano M; Hirayama F; Kuroda T; Uemori S; Moriguchi A; Yamamoto K; Ikeda Y; Kawakita T
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2185-90. PubMed ID: 9873510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.